Geode Capital Management LLC Increases Stake in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Geode Capital Management LLC increased its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 7.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,565,145 shares of the biotechnology company’s stock after purchasing an additional 182,914 shares during the period. Geode Capital Management LLC owned 2.23% of Coherus BioSciences worth $2,668,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Coherus BioSciences by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock worth $1,003,000 after buying an additional 116,217 shares during the period. Los Angeles Capital Management LLC raised its stake in Coherus BioSciences by 344.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after acquiring an additional 720,672 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Coherus BioSciences during the 2nd quarter worth about $1,246,000. XTX Topco Ltd grew its stake in Coherus BioSciences by 74.5% during the 3rd quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock valued at $492,000 after purchasing an additional 202,084 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Coherus BioSciences by 177.3% in the second quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company’s stock valued at $727,000 after purchasing an additional 268,763 shares during the period. Institutional investors and hedge funds own 72.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Coherus BioSciences in a report on Wednesday, December 4th. StockNews.com cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Finally, Robert W. Baird upped their price objective on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Stock Down 3.1 %

Coherus BioSciences stock opened at $1.57 on Wednesday. The business’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.27. The firm has a market cap of $180.88 million, a price-to-earnings ratio of -19.63 and a beta of 0.82. Coherus BioSciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.13.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.